<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161989</url>
  </required_header>
  <id_info>
    <org_study_id>IUGR-VP</org_study_id>
    <nct_id>NCT04161989</nct_id>
  </id_info>
  <brief_title>Omega 3 Plus Vaginal Progesterone on Birth Weight of Intrauterine Growth-restricted Fetuses</brief_title>
  <official_title>The Effect of Omega 3 and Vaginal Progesterone on Birth Weight and Doppler Velocimetry of Idiopathic Asymmetrically Intrauterine Growth-restricted Fetuses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrauterine growth restriction defines as the failure of the fetus to get its normal growth&#xD;
      and specific measures threshold along a normal centile. Intrauterine growth restriction is a&#xD;
      serious obstetric problem that affects about 10-15% of pregnant women. Those intrauterine&#xD;
      growth restriction babies have a great risk for perinatal morbidity and mortality. Many&#xD;
      causes are responsible for the development of asymmetrically intrauterine growth restriction,&#xD;
      however; in a few cases, the cause could not be detected so it is called idiopathic&#xD;
      intrauterine growth restriction. They are great controversies regarding the treatment of&#xD;
      idiopathic asymmetrically intrauterine growth restriction. The termination of pregnancy may&#xD;
      be preferable in some cases; however, the trials to improve blood flow to the uterus and/or&#xD;
      the fetus may be also beneficial.&#xD;
&#xD;
      Omega-3 fatty acids as antioxidants inhibit the release of the free radicals during pregnancy&#xD;
      so vasodilatation will occur. This leads to increase blood flow to the uterus and placenta&#xD;
      resulting in increasing amniotic fluid volume in cases of unexplained oligohydramnios and&#xD;
      improving pregnancy outcomes in intrauterine growth restriction fetuses.&#xD;
&#xD;
      Progesterone is a smooth muscle relaxant and has a vasodilator effect on the blood vessels.&#xD;
      It causes endothelium- relaxation of human placental arteries and veins. This relaxation is&#xD;
      significant for maintaining low flow impedance and satisfactory blood flow in the placental&#xD;
      circulation. DeFranco et al observed that the vaginal progesterone is associated with&#xD;
      vascular relaxation and increased uterine blood flow. In addition, he did not observe this&#xD;
      vascular effect in women receiving systemic progesterone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in mean birth weight (gram) of asymmetrical intrauterine growth restriction fetuses in both groups.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated fetal weight (gram)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of delivery (weeks)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Group I (omega-3 fatty acids group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (vaginal progesterone plus omega-3 group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acids</intervention_name>
    <description>. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% &amp; Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.</description>
    <arm_group_label>Group I (omega-3 fatty acids group)</arm_group_label>
    <arm_group_label>Group II (vaginal progesterone plus omega-3 group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal progesterone</intervention_name>
    <description>Prontogest 400 mg vaginal suppository contains progesterone 400 mg.</description>
    <arm_group_label>Group II (vaginal progesterone plus omega-3 group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gestational age between 28- 30 weeks.&#xD;
&#xD;
          2. Singleton pregnancy with idiopathic asymmetrical intrauterine growth restriction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multiple gestations.&#xD;
&#xD;
          2. Women with chronic diseases like hypertensive, diabetes mellitus, antiphospholipid&#xD;
             syndrome, systemic lupus erythematosus, renal diseases, cardiac diseases, blood&#xD;
             diseases ...etc.&#xD;
&#xD;
          3. Premature rupture of membranes.&#xD;
&#xD;
          4. Congenital fetal malformation.&#xD;
&#xD;
          5. Pregnancy was complicated by antepartum hemorrhage.&#xD;
&#xD;
          6. Low amniotic fluid volume at the time of recruitment (&lt; 5cm).&#xD;
&#xD;
          7. Women who known to have an allergy to vaginal progesterone.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed K ALi, MD</last_name>
      <phone>+201005537951</phone>
      <email>m_khairy2001@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

